缬沙坦与苯那普利对冠心病合并舒张功能异常的疗效分析

目的:探讨缬沙坦与苯那普利对冠心病合并舒张功能异常患者的临床疗效.方法:将58例冠心病合并舒张功能异常患者随机分成治疗组(30例)和对照组(28例).两组患者均给予冠心病常规治疗,治疗组加用缬沙坦(代文)80～160 mg/d,对照组加用苯那普利(洛汀新)10～20 m/d,疗程6个月.疗程结束后,评价患者的临床症状,测定左心室舒张功能指标的改善情况.结果:治疗组总有效率优于对照组(90%比57.1%,P＜0.05).结论:缬沙坦能改善冠心病合并舒张功能异常患者的预后,并能显著改善心脏舒张功能指标.

Clinical effect comparison of valsastan and benazepril on patients with coronary artery disease combined diastotic impaired function

Objective：To investigate the clinical effect of valsartan and benazepril on the patients with coronary artery disease combined diastolic impaired function.Methods：58 patients with coronary artery disease combined diastolic impaired function were divided into 2 groups：the first group was given valsartan on the basis of the conventional treatment,the another group was given benazepril for control.To compare the clinical curative effects between the two groups.Results：The total effective rate was 90% in the treatment group and 57.1% in the control group with statistical difference（P〈0.05）.No severe side effects were observed.Conclusion：The intravenous use of valsartan is safe and effective for coronary artery disease combined diastolic impaired function.